Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Industrifonden and Investinor in connection with a sale of shares in Calliditas
Mandate

Vinge has advised Industrifonden and Investinor in connection with a sale of shares in Calliditas

January 10, 2020 Capital Markets and Public M&A

Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately 2,300,000 shares in Calliditas Therapeutics AB (publ) to two investors for a total value of approximately USD 17,000,000.

Calliditas is listed on Nasdaq Stockholm and focuses on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

 Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

 Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

 Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026